Literature DB >> 9589360

New rodent models for studies of chemopreventive agents.

M Lipkin1.   

Abstract

Some recent studies of the effects of chemopreventive agents have begun to use new rodent models to improve the analysis of stages of colonic preneoplasia, and how chemopreventive agents modify progressive abnormal cell development. In one of the models of inherited predisposition to colon cancer, mice carrying a truncated Apc allele with a nonsense mutation in exon 15 have been generated by gene targeting and embryonic stem cell technology (Apc1638 mice). These mice develop multiple gastrointestinal lesions, including adenomas and carcinomas, focal areas of high-grade dysplasia (FAD), and polypoid hyperplasias with FADS. The incidence of inherited colonic neoplasms has now been modulated by a chemopreventive regimen. Colonic lesions significantly increased in Apc1638 mice on a Western-style diet, which has higher fat content and lower calcium and vitamin D compared to the same mice on AIN-76A diet. In another rodent model, Min mice were treated with sulindac, which markedly reduced the incidence of intestinal tumors. A third new rodent model containing a targeted mutation in the gene Mcc (mutated in colorectal cancer) recently became available for chemoprevention studies. These mice develop multiple types of neoplasms including adenocarcinomas, focal areas of gastrointestinal dysplasia, papillomas of the forestomach, and tumors in other organs including lung, liver, and lymphoid tissue. Feeding a Western-style diet to the Mcc mutant mice also resulted in significantly increased gastrointestinal lesions. These nutrient modifications also have been given to normal mice, demonstrating without any chemical carcinogen that a Western-style diet induced colonic tumorigenesis. Western-style diets also have now induced modulation of cell proliferation in other organs including mammary gland, pancreas, and prostate. These findings help develop new preclinical rodent models to aid the analysis of genetic and environmental factors leading to neoplasia, as well as new methods for evaluating the chemopreventive efficacy of specific nutrients and pharmacological agents.

Entities:  

Mesh:

Year:  1997        PMID: 9589360

Source DB:  PubMed          Journal:  J Cell Biochem Suppl        ISSN: 0733-1959


  7 in total

Review 1.  Mechanism of action of vitamin D and the vitamin D receptor in colorectal cancer prevention and treatment.

Authors:  Stephen W Byers; Tracey Rowlands; Marcy Beildeck; Yong-Sik Bong
Journal:  Rev Endocr Metab Disord       Date:  2012-03       Impact factor: 6.514

2.  Adenomatous polyposis coli protein (APC)-independent regulation of beta-catenin/Tcf-4 mediated transcription in intestinal cells.

Authors:  J Baulida; E Batlle; A García De Herreros
Journal:  Biochem J       Date:  1999-12-01       Impact factor: 3.857

3.  JNK1 is required for sulindac-mediated inhibition of cell proliferation and induction of apoptosis in vitro and in vivo.

Authors:  Zibo Song; Chang Tong; Jiao Liang; Ashley Dockendorff; Chuanshu Huang; Leonard H Augenlicht; Wancai Yang
Journal:  Eur J Pharmacol       Date:  2007-01-19       Impact factor: 4.432

4.  Sulindac suppresses beta-catenin expression in human cancer cells.

Authors:  Anjia Han; Zibo Song; Chang Tong; Dong Hu; Xiuli Bi; Leonard H Augenlicht; Wancai Yang
Journal:  Eur J Pharmacol       Date:  2008-02-05       Impact factor: 4.432

5.  Western-style diets induce oxidative stress and dysregulate immune responses in the colon in a mouse model of sporadic colon cancer.

Authors:  Ildiko Erdelyi; Natasha Levenkova; Elaine Y Lin; John T Pinto; Martin Lipkin; Fred W Quimby; Peter R Holt
Journal:  J Nutr       Date:  2009-09-16       Impact factor: 4.798

6.  Relationship between serum calcium and CA 19-9 levels in colorectal cancer.

Authors:  Peter Fuszek; Peter Lakatos; Adam Tabak; Janos Papp; Zsolt Nagy; Istvan Takacs; Henrik Csaba Horvath; Peter Laszlo Lakatos; Gabor Speer
Journal:  World J Gastroenterol       Date:  2004-07-01       Impact factor: 5.742

7.  Efficacy of EGFR inhibition is modulated by model, sex, genetic background and diet: implications for preclinical cancer prevention and therapy trials.

Authors:  Erica S Rinella; David W Threadgill
Journal:  PLoS One       Date:  2012-06-25       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.